Investors Capital Advisory Services’s Rosetta Genomics Ltd. ROSG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q2
$12K Sell
917
-66
-7% -$940 ﹤0.01% 710
2016
Q1
$12K Buy
983
+66
+7% +$842 ﹤0.01% 689
2015
Q4
$13K Sell
917
-333
-27% -$7.18K ﹤0.01% 706
2015
Q3
$37K Sell
1,250
-479
-28% -$16.3K 0.01% 689
2015
Q2
$70K Buy
+1,729
New +$73.9K 0.01% 694

Other funds holding ROSG

Investors Capital Advisory Services's ROSG Position: Q2 2016 in Review

Investors Capital Advisory Services reduced its Rosetta Genomics Ltd. (ROSG) stake by 6.7% in Q2 2016, selling an estimated $940 and leaving 917 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #710.

Investors Capital Advisory Services first reported a position in ROSG in Q2 2015 and has held it in 5 quarters since. The position peaked at $70K in Q2 2015. 10 funds tracked by Wall St. Rank hold ROSG as of Q2 2016.

  • Investors Capital Advisory Services held 917 shares of Rosetta Genomics Ltd. worth $12K as of Q2 2016.
  • Investors Capital Advisory Services sold 66 Rosetta Genomics Ltd. shares in Q2 2016, an estimated $940.
  • Rosetta Genomics Ltd. made up ﹤0.01% of Investors Capital Advisory Services's portfolio in Q2 2016, its #710 holding.
  • Investors Capital Advisory Services first reported a position in Rosetta Genomics Ltd. in Q2 2015 and has held it in 5 quarters since.
  • Investors Capital Advisory Services's Rosetta Genomics Ltd. position peaked at $70K in Q2 2015.
  • 10 funds tracked by Wall St. Rank held Rosetta Genomics Ltd. as of Q2 2016.

Based on Investors Capital Advisory Services's 13F filing for Q2 2016, filed 2 Aug 2016.